Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK1 | P23458 | 4/20 | 0.42 |
| ▸ | JAK2 | O60674 | 3/20 | 0.42 |
| ▸ | TYK2 | P29597 | 3/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.35 |
| ▸ | JAK3 | P52333 | 1/20 | 0.32 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.31 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | NAMPT | P43490 | 1/20 | 0.30 |
| ▸ | PDCD1 | Q15116 | 1/20 | 0.30 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.30 |
| ▸ | PHGDH | O43175 | 1/20 | 0.30 |
| ▸ | MGLL | Q99685 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21757037 | 0.89 | JAK2 (0.45) | JAK1JAK2TYK2ALDH1A1NPC1 | |
| SCHEMBL21757053 | 0.86 | JAK2 (0.43) | JAK1JAK2TYK2ALDH1A1NPC1 | |
| SCHEMBL12385899 | 0.81 | ALDH1A1 (0.58) | ALDH1A1NPC1EPHX2MEN1KMT2A | |
| SCHEMBL21757145 | 0.79 | JAK2 (0.41) | JAK1JAK2TYK2ALDH1A1NPC1 | |
| SCHEMBL23240355 | 0.77 | SMN1; SMN2 (0.45) | ALDH1A1NPC1EPHX2HPGD | |
| SCHEMBL17266094 | 0.77 | ALDH1A1 (0.41) | ALDH1A1NPC1TLR8TLR7MEN1 | |
| SCHEMBL27256663 | 0.77 | NPC1 (0.49) | ALDH1A1NPC1EPHX2MEN1KMT2A | |
| SCHEMBL21756990 | 0.74 | JAK1 (0.42) | JAK1JAK2TYK2ALDH1A1NPC1 | |
| SCHEMBL15987021 | 0.72 | ALDH1A1 (0.33) | ALDH1A1NPC1MEN1KMT2AHPGD | |
| SCHEMBL21756991 | 0.71 | CHRM4 (0.40) | JAK1JAK2TYK2ALDH1A1NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4105214-A1 | USE OF JAK INHIBITORS IN PREPARATION OF DRUGS FOR TREATING JAK KINASE-RELATED DISEASES | Zhuhai United Laboratories Co., Ltd (CN) | 2022-12-21 | — | — | EP | disclosed |
| WO-2022161205-A1 | ORAL PREPARATION CONTAINING JAK INHIBITOR OR SALT THEREOF OR CRYSTAL FORM THEREOF, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF | 珠海联邦制药股份有限公司 | 2022-08-04 | — | — | WO | disclosed |
| WO-2021159372-A1 | USE OF JAK INHIBITORS IN PREPARATION OF DRUGS FOR TREATING JAK KINASE-RELATED DISEASES | 珠海联邦制药股份有限公司 | 2021-08-19 | — | — | WO | disclosed |
| EP-3842431-A1 | [1,2,4]TRIAZOLO[1,5-A]PYRIDINE COMPOUND AS JAK INHIBITOR AND APPLICATION THEREOF | Zhuhai United Laboratories Co., Ltd (CN) | 2021-06-30 | — | — | EP | disclosed |
| US-20210155621-A1 | [1,2,4]TRIAZOLO[1,5-A]PYRIDINE COMPOUND AS JAK INHIBITOR AND USE THEREOF | ZHUHAI UNITED LABORATORIES CO., LTD. (CN) | 2021-05-27 | — | — | US | disclosed |
| WO-2020038457-A1 | [1,2,4]TRIAZOLO[1,5-A]PYRIDINE COMPOUND AS JAK INHIBITOR AND APPLICATION THEREOF | 珠海联邦制药股份有限公司 | 2020-02-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210155621-A1 | [1,2,4]TRIAZOLO[1,5-A]PYRIDINE COMPOUND AS JAK INHIBITOR AND USE THEREOF | JAK1, JAK2, TYK2 | JAK1 1/4885JAK2 2/4885TYK2 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.